Meet the Street: Sifting Through the Biotech Bust-Up

There isn't a painkiller strong enough to numb the spirits of biotech investors so far this year. The American Stock Exchange Biotech Index is down more than 12%, as the ImClone Systems(IMCL Quote) debacle, a sector rotation out of biotech into technology and Enronitis all take their toll.

TheStreet.com spoke recently with Jim Fiore, a fund manager with Greenwich, Conn.-based Life Sciences Group, seeking some balm for biotech investors' wounds.

Jim Fiore, Fund Manager, Life Sciences Group

Recent Meet the Streets

New York Life Benefit Services' Mark Niziak

VegasInsider.com's Cesar Robaina

Author, Rob Adams

Cotto & Padovani's James R. Cotto

George Washington University's Lawrence Mitchell

Author James K. Glassman

Lehman Brothers' Bob Willens

...